LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Today MAX BioPharma, Inc. (www.maxbiopharma.com) and Metaba, LLC (www.metaba.us) announced their collaboration in studying the effects of oxysterol drug candidates that target non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), chronic inflammation, and atherosclerosis on metabolic processes using Metaba's state of the art metabolomics platform technology. The two companies will employ their unique expertise and assets to identify changes in metabolites induced by oxysterols that may not only further evaluate the mechanism of action for their therapeutic effects, but also identify potential biomarkers for assessment of the efficacy of the compounds or as diagnostic and prognostic tools.
LOS ANGELES, Sept. 13, 2021 /PRNewswire/ -- Max BioPharma, Inc. (www.maxbiopharma.com) recently published an article that reported the efficacy of its anti-fibrotic and anti-inflammatory oxysterol lead compound, Oxy210, in the peer-reviewed journal, Endocrinology, Diabetes & Metabolism.
LOS ANGELES, Feb. 2, 2021 /PRNewswire/ -- In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, Max BioPharma (www.maxbiopharma.com) scientists have identified new substances with antiviral activity against the novel coronavirus, SARS-CoV-2, the virus that caused the ongoing global COVI